[[Galeterone]]

CATEGORIES: Experimental cancer drugs

Galeterone (TOK-001 or VN/124-1) is an experimental drug being developed by Tokai Pharmaceuticals, Inc. for the treatment of prostate cancer. It is both an androgen receptor antagonist and CYP17A1 inhibitor.[tpl]cite journal | author = Brawer MK | title = New treatments for castration-resistant prostate cancer: highlights from the 44th annual meeting of the american society of clinical oncology, may 30-june 3, 2008, chicago, IL | journal = Rev Urol | volume = 10 | issue = 4 | pages = 294â€“6 | year = 2008 | pmid = 19145273 | pmc = 2615106 | doi = [/tpl] It is currently being tested in early phase I/II clinical trials for castration resistant prostate cancer.[tpl]cite web | url = http://clinicaltrials.gov/ct2/show/NCT00959959 | title = NCT00959959 | work = | publisher = ClinicalTrials.gov, United States National Institutes of Health | quote = ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer | accessdate = 2011-09-25 [/tpl]

==See also==

==References==


